Hakan Kardes is Chief Experience Officer at Alignment Healthcare, Inc. (ALHC). They have made 7 open-market trades across 1 company since 2024, most recently 2025-03-27.
CIK 0001975023
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ALHC | 678,987 | $5.5M |
Shares reported on the most recent Form 4, priced at the 2025-03-28 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ALHC | SELL | 2025-03-27 | 2025-03-28 | $17.89 | $259K | +2.7% | -2.0% | -23.8% |
| ALHC | SELL · 10b5-1 | 2025-03-18 | 2025-03-19 | $16.88 | $1.0M | +11.2% | +4.5% | -13.0% |
| ALHC | SELL | 2025-03-12 | 2025-03-13 | $15.42 | $149K | +13.9% | +23.8% | -0.1% |
| ALHC | SELL | 2025-03-06 | 2025-03-06 | $15.53 | $2.7M | +9.0% | +16.0% | -0.3% |
| ALHC | SELL · 10b5-1 | 2025-01-24 | 2025-01-24 | $14.98 | $217K | +6.5% | -7.3% | +22.6% |
| ALHC | SELL · 10b5-1 | 2025-01-21 | 2025-01-23 | $14.99 | $157K | +6.6% | -6.0% | +26.2% |
| ALHC | SELL | 2024-11-27 | 2024-11-29 | $12.80 | $448K | -7.5% | -12.0% | +6.2% |
| ALHC | SELL · 10b5-1 | 2024-11-01 | 2024-11-05 | $13.05 | $326K | -18.0% | -12.9% | +9.8% |
| ALHC | SELL · 10b5-1 | 2024-09-12 | 2024-09-13 | $11.48 | $287K | -5.9% | -4.8% | -7.0% |
| ALHC | SELL · 10b5-1 | 2024-07-16 | 2024-07-18 | $9.98 | $250K | -12.4% | -14.1% | +18.0% |
| ALHC | SELL | 2024-03-28 | 2024-03-29 | $4.84 | $21K | -4.0% | +2.4% | +58.3% |
| ALHC | SELL | 2024-03-19 | 2024-03-21 | $5.05 | $192K | -7.8% | +3.3% | +46.2% |
| ALHC | SELL | 2024-03-15 | 2024-03-15 | $4.89 | $21K | -1.2% | -2.9% | +67.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.